USC experts can discuss newly approved Alzheimer’s drug and related dementia research

Source Alert

USC experts can discuss newly approved Alzheimer’s drug and related dementia research

July 02, 2024

The US Food and Drug Administration on Tuesday approved a new drug designed to slow the progression of early symptomatic Alzheimer’s disease. The drug, donanemab, was shown in studies to modestly slow cognitive decline in initial stages of the disease but it also carries safety risks. USC experts can speak about the potential impact of amyloid-clearing medications.

Contact: Leigh Hopper at lhopper@usc.edu or uscnews@usc.edu

Helena Chui can discuss potentially serious side effects of new Alzheimer’s drugs which include brain swelling and bleeding.

Paul Aisen can discuss amyloid-clearing drugs for Alzheimer’s disease. Aisen is the founding director of the Alzheimer’s Therapeutic Research Institute of USC (ATRI).

Lon Schneider is an expert on psychiatry, dementia prevention, intervention and care.

Elizabeth Joe sees Alzheimer’s patients in the clinic and can speak about diagnosing the disease and issues facing families.

Julie Zissimopoulos focuses on the economic costs of dementia, the impact of dementia on care partners, and racial and ethnic disparities in diagnosis and health care treatment for dementia.

María Aranda can discuss the burden of dementia in Black and Latino populations and how to diversify clinical trials. Aranda is the director of outreach, recruitment and engagement at the Alzheimer’s Disease Research Center at USC.

Donna Benton can discuss the challenges faced by caregivers, including the aging parents of people with Down syndrome, who are susceptible to developing Alzheimer’s in middle age.

Hussein Yassine specializes in how changes in lipid metabolism and nutrition affect cognition and the risk of developing Alzheimer’s disease. He directs a new center for patients who carry the APOE4 allele, the strongest genetic risk factor for dementia.

Additional USC experts

The economics of aging

Dana Goldman can discuss health policies that impact patients with dementia and their caregivers.

Soeren Mattke studies the economic, political and societal implications of Alzheimer’s treatment.

Arie Kapteyn’s recent work is in the field of aging and economic decision making, with papers on topics related to retirement, consumption and savings, disability and economic well-being of the elderly.

Alzheimer’s origins

Andrew Petkus, Caleb Finch and Jiu-Chiuan (JC) Chen  explore the link between fine-particle pollution and Alzheimer’s disease. 

Andrei Irimia is a biogerontologist and computational neurobiologist studying the effects of genetic, epigenetic, and environmental factors on brain aging. He’s looked at Indigenous populations in the Bolivian Amazon to understand healthy brain aging.

Margaret Gatz researches age-related change in depressive symptoms, personality, and cognition; and risk and protective factors for Alzheimer’s disease and other dementias.

John Ringman is an expert on the Jaliso gene, which predisposes people to developing Alzheimer’s in their 40s.

Michael Rafii can discuss the link between Down syndrome and Alzheimer’s.

Zhen Zhao researches the genetic causes of vascular cognitive impairment and dementia.

Sean Curran is an expert in the biological mechanisms of aging, nutrition and stress adaptation.  

Eileen Crimmins has led decades of research focused on how health changes over the life cycle, as well as differences in chronological and biological age.

Brain imaging, mapping, data

Art Toga is an expert in brain mapping. He is a Provost Professor of Ophthalmology, Neurology, Psychiatry, and the Behavioral Sciences, Radiology, Engineering and Biological Sciences at the Keck School of Medicine of USC.

Neda Jahanshad researches genetic influences on brain structure using high-resolution structural and diffusion imaging. Her work with diffusion imaging involves monitoring the effects of infectious diseases, such as HIV, on the brain.

Paul Thompson is principal investigator and co-founder of a consortium which has cooperatively analyzed data from over 45 countries to publish the largest worldwide neuroimaging studies of over 15 brain diseases and conditions, including Parkinson’s disease, epilepsy, ataxia and brain injury, PTSD, substance use disorder, bipolar disorder, major depression, and neurodevelopmental conditions including OCD, ADHD, and ASD.

# # #

 

Post Dobbs, some states saw deep declines in prescriptions for birth control and emergency contraceptive pills

Medication

News Releases

Post Dobbs, some states saw deep declines in prescriptions for birth control and emergency contraceptive pills

June 26, 2024

Contact: Leigh Hopper at lhopper@usc.edu

Women residing in states with the most restrictive abortion policies after the Supreme Court’s reversal of Roe v Wade also experienced declines in the use of birth control pills and emergency contraceptives, according to a new USC study evaluating the impact of the decision.

The findings, which appear today in JAMA Network Open, suggest that the Dobbs v. Jackson Women’s Health Organization case has had even wider ramifications for women’s reproductive health than previously thought.

The analysis found that states that became that most restrictive after Dobbs, implementing a full ban on abortion, saw significant declines in the number of prescriptions filled for birth control pills and emergency contraceptives at retail pharmacies. These reductions weren’t observed in restrictive states whose policies were unchanged after the Dobbs decision.

Many family planning clinics with abortion services closed immediately after the Roe reversal—particularly in the most restrictive states, said lead author Dima M. Qato, the Hygeia Centennial Chair and associate professor at the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences of USC.

“Because 11% of women rely on such clinics for the provision of prescriptions for contraceptives – many of which are filled at outside pharmacies – these closures may have reduced access to oral and emergency contraceptives,” Qato said.

What’s more, the Supreme Court decision may also have contributed to declines in the use of emergency contraceptives due to misunderstandings about their legality. A January 2023 survey by the Kaiser Family Foundation found that half of women in full-ban states believed Plan B was illegal in their state.

This is the first national study to evaluate the impact of the court’s June 24, 2022, Dobbs decision on prescription fills for oral and emergency contraceptives in the United States.

Efforts needed to protect access

Qato led a team which examined changes in the use of prescription birth control pills and emergency contraceptives before and after the Dobbs decision. During the time period analyzed, March 2021 and October 2023, 142.8 million prescriptions for oral contraceptive pills and 904,269 prescriptions for emergency contraceptives were dispensed at U.S. retail pharmacies.

Before Roe’s reversal, trends in monthly prescription rates for oral and emergency contraception were similar between the most restrictive and least restrictive states. Then, while the case was being reviewed, more highly restrictive states saw a spike in emergency contraceptive prescriptions.

After the decision, however, the researchers found that states becoming the most restrictive experienced a 24% total decline in oral contraceptive prescriptions filled. Fills for emergency contraceptives declined by 65% in the most restrictive states compared to less restrictive ones.

“In states such as Texas and Mississippi where women now don’t even have the option to have an abortion, their access to contraception is also becoming more difficult,” said Qato. “More efforts to improve and protect access to oral contraceptives are needed, especially for emergency contraceptives in states where abortion is no longer an option.”

Researchers noted that emergency contraceptive fills post-Dobbs increased the most in Idaho, which, among states with the most restrictive abortion policies, is the only one that allows pharmacists to prescribe emergency contraceptives to women without any age restrictions.

“We saw the greatest declines in birth control pills and emergency contraceptives in states that had closed a larger share of their family planning clinics. In Texas, for example, birth control pill prescriptions declined by 28% and emergency contraceptive fills declined by 48%,” said Rebecca Myerson, a Schaeffer Fellow and assistant professor at UW Madison who worked on the study.

About this study

Data for the study came from three sources: IQVIA National Prescription Audit PayerTrak, to estimate the monthly volume of prescriptions dispensed at pharmacies at the national and state level; the 2021 American Community Survey, to determine the total population of women and girls of reproductive age; and the Guttmacher Institute, to classify each state in terms of changes in policies related to abortion restrictions between June 2022 and October 2023.

In addition to Qato and Myerson, other authors include co-author G. Caleb Alexander, professor of epidemiology and medicine at the Johns Hopkins Bloomberg School of Public Health; UC Berkeley assistant professor Jenny S. Guadamuz, a former postdoctoral research fellow at the Schaeffer Center; and USC Mann research affiliate Andrew Shoostari.

Qato directs USC Mann’s Program on Medicines and Public Health and is a senior fellow at the USC Schaeffer Center for Health Policy & Economics. The Schaeffer Center is a partnership between USC Mann and the USC Sol Price School of Public Policy.

‘More efforts to improve and protect access
to oral contraceptives are needed, especially for
emergency contraceptives in states where
abortion is no longer an option.’

— Dima Qato, USC Mann

# # #